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Background: Red ginseng is prepared by steaming raw ginseng, a process believed to increase the
pharmacological efficacy. Further bioconversion of red ginseng through fermentation is known to increase its
intestinal absorption and bioactivity, and bioconversion diminishes the toxicity of red ginseng’s metabolite. This
study was conducted to investigate the effects of daily supplementation with fermented red ginseng (FRG) on
glycemic status in subjects with impaired fasting glucose or type 2 diabetes.
Methods: This study was a four-week long, randomized, double-blind, placebo-controlled trial. Forty-two subjects
with impaired fasting glucose or type 2 diabetes were randomly allocated to two groups assigned to consume
either the placebo or fermented red ginseng (FRG) three times per day for four weeks. Fasting and postprandial
glucose profiles during meal tolerance tests were assessed before and after the intervention.
Results: FRG supplementation led to a significant reduction in postprandial glucose levels and led to an increase in
postprandial insulin levels compared to the placebo group. There was a consistently significant improvement in the
glucose area under the curve (AUC) in the FRG group. However, fasting glucose, insulin, and lipid profiles were not
different from the placebo group.
Conclusion: Daily supplementation with FRG lowered postprandial glucose levels in subjects with impaired fasting
glucose or type 2 diabetes.
Trial registration: ClinicalTrials.gov: NCT01826409
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Type 2 diabetes is the fastest-growing metabolic disorder
in many parts of the world. The incidence of type 2 dia-
betes in 2000 was ~171 million worldwide, and the num-
ber is estimated to double by 2020 [1,2]. Type 2 diabetes
patients have a higher risk of cardiovascular disease, and
recent studies have also suggested that impaired fasting* Correspondence: pts@jbnu.ac.kr; soowan@jbnu.ac.kr
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unless otherwise stated.glucose and impaired glucose tolerance are risk factors for
cardiovascular disease independent of type 2 diabetes [3].
Therefore, patients with impaired fasting glucose or im-
paired glucose tolerance have become an important target
group for the primary prevention of cardiovascular disease.
Ginseng, which is derived from the root of Panax gin-
seng C.A. Meyer, has been used for centuries in health-
promoting supplements in Asia. The crude ginseng extract
exhibits many bioactivities, including anticancer, antidia-
betic, anti-inflammatory, antioxidant, and immunomodula-
tory effects [4-7]. When ginseng is steamed before drying,
it is called red ginseng, and its bioactivity seems to offer
more potential uses than the unprocessed white ginseng. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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various saponins (ginsenosides, a group of triterpene glyco-
sides) and non-saponins, with the pharmacological activity
of red ginseng attributable mainly to these ginsenosides
[9,10]. To date, 50 ginsenosides have been identified in red
ginseng. In the gastrointestinal tract, these ginsenosides are
further metabolized by intestinal microorganisms, which
improves their intestinal absorption, increases bioactivity,
and diminishes the toxicity of the metabolite [11,12].
According to the literature, fermentation using microor-
ganisms for the production of more effective compounds
has been extensively studied. In particular, the pharmaco-
logical effects of a new saponin generated by red ginseng
fermentation have been reported, and this saponin can be
mass produced. Fermented red ginseng (FRG) can be me-
tabolized by intestinal microorganisms, resulting in the
transformation of ginsenosides Rb1, Rb2, Rc, and Rd into
compound K, which is active in cancer, diabetes, and im-
mune stimulation [13]. Also, fermentation of ginseng
using lactic acid bacteria (Bifidobacterium sp., Lactobacil-
lus sp., etc.) transforms Rg3 into Rh2, and this biotrans-
formation increases cytotoxicity against tumor cells,
potentiates an anti-allergic effect against mast cells, and
exhibits anti-inflammatory activity [14-18]. These studies
demonstrate that fermentation of red ginseng transforms
its pharmacological ingredients into low molecular weight
active compounds and results in greater absorption.
In recent years, studies have reported that fermentation
increases the hypolipidemic and hypoglycemic effects of
red ginseng [18], and FRG protects pancreatic β-cells from
streptozotocin toxicity [19]. However, to our knowledge,
functional studies regarding the anti-diabetic effects of
FRG in humans have never been conducted. In this study,
red ginseng was subjected to fermentation with Lactoba-
cillus plantarum, and the postprandial glucose-lowering
activity of FRG was investigated in subjects with impaired
fasting glucose or type 2 diabetes.
Methods
Participants
The study subjects were recruited from May 2008 to
August 2009 in the Clinical Trial Center for Functional
Foods at Chonbuk National University Hospital via a local
newspaper advertisement. A total of 42 healthy male and
female subjects agreed to participate in the study. Subjects
age 20–75 years with a fasting glucose of 5.6-7.8 mmol/l
with at least two follow-up measurements were recruited
and included in the study. Exclusion criteria for the study
included the following: (1) a history of diabetes mellitus or
glucose-lowering agent use or insulin therapy within three
months prior to screening, (2) lipid metabolism disorders,
(3) acute or chronic inflammatory disease, (4) corticoster-
oid medication use within weeks of the study, (5) cardio-
vascular disease (arrhythmia, heart failure, myocardialinfarction, or patients with pacemakers), (6) an allergy or
hypersensitivity to any of the ingredients in the test prod-
ucts, (7) a history of disease that could interfere with the
test products or impede their absorption, such as gastro-
intestinal diseases (Crohn’s Disease) or gastrointestinal sur-
gery (appendicitis or enterocele), (8) participation in other
clinical trials within the previous two months, (9) abnormal
hepatic liver function or renal disease (acute/chronic renal
failure or nephrotic syndrome), (10) use of medication con-
taining lipid phosphates within three months of the study,
(11) use of anti-psychosis drug therapy within two months
of the study, (12) laboratory tests, medical, or psychological
conditions deemed by the investigators to interfere with suc-
cessful participation in the study, (13) a history of alcohol or
substance abuse, and (14) pregnancy or current breast feed-
ing. All subjects gave their written, informed consent before
entering the study. The study, which was conducted accord-
ing to the Declaration of Helsinki, was approved by the
Functional Food Institutional Review Board (FFIRB) of
Chonbuk National University Hospital (WKP-FG7070-001).
Preparation of FRG
Fermented red ginseng extract was provided by WON
PHARM Co., Ltd. (Iksan, Korea). The red ginseng was
prepared by steaming the root of Panax ginseng C.A.
Meyer (at least four-year-old white ginseng) at 98-100 for
4 h and drying the ginseng at 60°C for 5 h. Next, the fer-
mented red ginseng was extracted with 60% ethyl alcohol
at 70°C. The red ginseng extract was suspended in water,
fermented for 15 days by previously cultured Lactobacillus
plantarum at 35-40°C, and then freeze-dried. Ginsenoside
profiles in the FRG were analyzed by high performance li-
quid chromatography (HPLC) according to Korean Food
and Drug Administration (KFDA) guidelines, and these
ginsenoside profiles are shown in Table 1. The placebo
was composed primarily of dried yeast, and the flavor, en-
ergy content, appearance, and dosage were matched.
Study design
This study was a four-week long, randomized, double-
blind, placebo-controlled clinical trial, performed according
to a computer-generated randomization schedule designed
to assign subjects to the FRG or placebo groups. Neither
the investigators nor the subjects knew the randomization
code or the results of the blood glucose levels until after
statistical analysis was complete. Subjects attended a
screening visit (within two weeks), at which inclusion and
exclusion criteria were assessed. The enrolled subjects were
scheduled for their first visit, and subjects were randomly
assigned to one of two groups, either the FRG (n = 21) or
placebo group (n = 21). Subjects received either the FRG or
placebo capsules every week, and all subjects were
instructed to take either three FRG capsules or three pla-
cebo capsules per day (2.7 g/day) for four weeks.
Table 1 Ginsenoside profile of the FRG








Compound K 0.05 0.49
Total 1.77 2.35
*Determined by high performance liquid chromatography (HPLC).
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every week for a total six visits, which included the screen-
ing visit (screening, 0, 1, 2, 3 and 4 weeks). After the sub-
jects were screened, we performed a meal tolerance test.
The subjects were asked to consume a standard meal
[584.1 kcal, caloric contribution: 52% carbohydrates (con-
taining 70 g of available carbohydrate), 18% protein, and
30% fat] after a 12-h overnight fast. To determine the post-
prandial glucose and insulin responses, venous blood sam-
ples were taken at 0, 30, 60, 90, and 120 min. The 0 min
sample was used to determine fasting plasma glucose and
insulin levels. Also, fasting blood samples were collected at
each visit to measure laboratory parameters and the lipid
profile (total cholesterol, HDL cholesterol, LDL cholesterol,
and triglycerides). During the assessment period, subjects
were instructed to sit quietly.
During the intervention period of four weeks, subjects
were asked to continue their usual diets and activity and
to not ingest any other functional foods or dietary supple-
ments. Anthropometric and biochemical parameters, vital
signs, and nutrient intake were measured before and after
the intervention period. Every week, the subjects were
asked to report any adverse events or changes in training,
lifestyle, or eating pattern, and to assess capsule-dosing
compliance.
A CONSORT checklist for the reporting of this study
can be found in Additional file 1.Biochemical analyses
Blood samples were analyzed on a Hitachi 7600–110
analyzer (Hitachi High-Technologies Corporation, Japan).
The total area under the curve (AUC) of the glucose re-
sponse during the meal tolerance tests was determined
using the trapezoid method.
Safety was assessed by adverse events, physical examin-
ation, vital signs, and laboratory parameters (hematology,
biochemistry, and urinalysis). Finally, compliance was
assessed by the number of returned capsules.Statistical analysis
All of the presented data are from the intention-to-treat
population. The primary outcome (postprandial glucose)
and the secondary outcomes (total cholesterol, HDL chol-
esterol, LDL cholesterol, and triglycerides) were used to
compare the FRG group to the placebo group. Statistical
analyses were performed using SAS version 9.2 for Win-
dows (SAS Institute, Cary, NC, USA). For statistics, we
used a mixed-effect model approach for intention-to-treat
analysis with missing values [20]. Data are shown as the
mean values and the standard error of the mean (SEM).
The sample size was statistically determined to obtain a
power of 80% with an alpha of 0.05. In order to demon-
strate effects in 2-h postprandial glucose level, which was
calculated to be a 0.4 mmol/l reduction with a standard de-
viation of 0.53 mmol/l, a sample size of 32 (16 in the FRG
group and 16 in the placebo group) was required. Assum-
ing a 20% loss to follow-up, 42 participants were selected.
The two groups were equal in size in order to obtain the
greatest statistical power. General characteristics were ana-
lyzed by independent t-tests or Chi-square tests. The signifi-
cance of the differences within or between groups were tested
by a linear mixed-effect model and a paired t-test of the mean.
Chi-square tests were performed to determine differences in
the frequencies of categorized variables between groups. A
value of p < 0.05 was considered statistically significant.
Results
Participant characteristics
Eighty-four participants were assessed for eligibility, and a
total of 42 participants (mean age = 53.3 ± 8.4 years, 28
males and 14 females, mean body mass index = 24.9 ±
3.3 kg/m2, fasting glucose = 6.5 ± 0.5 mmol/l) met the in-
clusion criteria. Nineteen participants were diagnosed with
type 2 diabetes, and 23 participants had either impaired
fasting glucose or impaired glucose tolerance. Among
these participants, six dropped out for reasons which in-
cluded lack of compliance (n = 2), administration of a pro-
hibited drug (n = 1), withdrawal of consent (n = 2), and an
adverse event (n = 1). Thus, a total of 36 participants com-
pleted the study (Figure 1). There were no significant dif-
ferences between the two groups in age, gender, height,
weight, body mass index, or fasting glucose levels (Table 2).
The compliance rates, which were based on pill count,
were 95.6 ± 4.8% and 95.4 ± 5.1% in the placebo and FRG
groups, respectively. The diabetic participants did not re-
ceive antihyperglycemic medication or insulin therapy,
and no participants with impaired fasting glucose or im-
paired glucose tolerance were newly diagnosed with type 2
diabetes during the study.
Safety
At each visit, information about symptoms or side ef-
fects was recorded, but no severe side effects or serious
Figure 1 Disposition of participants in the clinical trial of FRG versus placebo. Number of study participants enrolled, allocated, followed,
and analyzed, shown using the CONSORT 2010 Flow Diagram.






Sex (M/F) 15/6 13/8 0.5132)
Age (years) 53.5 ± 1.9 53.2 ± 1.8 0.914
Height (cm) 165.0 ± 1.8 166.6 ± 1.4 0.477
Weight (kg) 67.5 ± 2.4 68.9 ± 1.8 0.646
Waist (cm) 91.1 ± 1.7 93.0 ± 1.3 0.406
BMI (kg/m2) 24.9 ± 0.8 24.9 ± 0.7 1.000
Fasting plasma
glucose (mmol/l)
6.4 ± 0.6 6.5 ± 0.5 0.737
Total cholesterol (mmol/l) 4.8 ± 0.1 5.2 ± 0.2 0.121
LDL cholesterol (mmol/l) 2.9 ± 0.1 3.1 ± 0.1 0.414
HDL cholesterol (mmol/l) 1.2 ± 0.1 1.3 ± 0.1 0.170
Triglycerides (mmol/l) 1.7 ± 0.1 1.7 ± 0.1 0.928
Data are presented as mean ± SEM. 1)Analyzed by independent t-tests and the
p-value represents the comparison to the placebo group. 2)Analyzed by
Chi-square tests. BMI: body mass index.
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study period. However, hypoglycemia was reported in
the FRG group, which led to one subject withdrawing
from the study.Meal tolerance test
The effects of FRG supplementation on postprandial gly-
cemic variables were evaluated during a standardized
breakfast test meal. Compared to the placebo, FRG sup-
plementation significantly reduced the 2-h postprandial
glucose level and increased the 2-h postprandial insulin
level (Table 3). The fasting plasma glucose level was sig-
nificantly reduced by FRG supplementation (p = 0.039),
but did not show a treatment effect when compared to the
placebo group. No differences in the fasting insulin level
were found. Figure 2 shows the time-course changes in
the plasma glucose levels during the meal tolerance test.
Consistent with the significant change in the 2-h post-
prandial glucose level (p = 0.008), there was a significant
difference in the AUC of the glucose response between
the placebo and FRG groups (Table 3).
Table 3 Effect of FRG supplementation on postprandial glucose and insulin levels
Placebo group (n = 21) FRG group (n = 21) p-value2)
Baseline Week 4 p-value1) Baseline Week 4 p-value1)
Fasting plasma glucose (mmol/l) 6.4 ± 0.61 6.3 ± 0.6 NS 6.5 ± 0.5 6.1 ± 0.6 0.039 NS
Postprandial plasma glucose2h (mmol/l) 9.0 ± 2.1 8.5 ± 1.9 NS 9.3 ± 2.2 7.7 ± 1.9 0.0001 0.008
AUCglucose (mmol/l) 18.4 ± 0.7 17.3 ± 0.7 0.045 18.6 ± 0.7 13.5 ± 1.6 0.002 0.013
Fasting plasma insulin (μU/ml) 7.4 ± 0.9 6.9 ± 0.6 NS 7.3 ± 1.0 9.0 ± 1.3 NS NS
Postprandial plasma insulin2h (μU/ml) 38.1 ± 3.9 35.5 ± 4.1 NS 39.2 ± 5.6 56.3 ± 9.8 NS 0.040
1)Analyzed by linear mixed-effect model and the p-value represents the comparison to the baseline visit. 2)Analyzed by linear mixed-effect model and the p-value
represents the comparison to the placebo group. Data are presented as the mean ± SEM.
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After four weeks of supplementation, there were no sig-
nificant differences in total cholesterol, HDL-cholesterol,
LDL-cholesterol, or triglyceride levels between the FRG
and placebo groups (Table 4).
Discussion
Over the past few decades, various plant extracts have been
clinically evaluated for the treatment of type 2 diabetes, in-
cluding red ginseng, which has been shown to possess anti-
diabetic activity in cell cultures, animal studies, as well as in
clinical studies [21-23]. To enhance the pharmacological ef-
ficacy of red ginseng, bioconversion using intestinal bacteria
has been successfully implemented. During bacterial fer-
mentation, ginsenosides are transformed into their readily
absorbable and more potent deglycosylated forms. Be-
cause of the benefits this transformation confers, several
intestinal bacteria have been used to ferment red ginseng,
and the selection of an appropriate bacterial strain has be-
come an essential prerequisite in achieving red ginseng’s
desired pharmacological efficacy. In this study, we used L.
plantarum for the microbial conversion of ginsenosides inFigure 2 The effect of FRG supplementation on glucose levels
during meal tolerance tests. Data are shown as mean ± SEM for
21 subjects. **p < 0.01 vs. placebo at four weeks.red ginseng. L. plantarum has been traditionally used for
kimchi fermentation and is considered to be a food-grade
microorganism [24]. Using this bacteria, Kim et al. [25]
found that fermented red ginseng contains a much higher
concentration of total ginsenosides and metabolites, espe-
cially Rh1, Rh2, Rg5, Rk1, Rg2, Rg3, and compound K. Of
note, FRG has enhanced immunological activities com-
pared to red ginseng [26]. However, no studies have been
conducted in which fermented red ginseng was used to
treat diabetic patients.
The rationale for FRG supplementation in patients with
impaired fasting glucose or type 2 diabetes is based on
several reports. Ginseng is effective in the prevention of
diabetes development in high-risk patients, and ginseng
also improves glycemic control in patients with type 2 dia-
betes [27]. Notably, red ginseng supplementation reduces
postprandial glycemia and improves symptoms in patients
with type 2 diabetes [28,29]. Pharmacokinetic analysis of
ginsenoside metabolites demonstrates a greater absorption
rate of compound K in fermented ginseng than in non-
fermented ginseng [30]. Also, fermentation of red ginseng
berries with L. plantarum improves blood glucose parame-
ters in diabetic db/db mice [31]. These studies suggest that
fermentation may potentiate the action of red ginseng on
the insulin-secreting pancreatic β-cells and the target tis-
sues that take up glucose.
Our finding of reduced postprandial glucose levels and
increased insulin levels in the FRG group during the meal
tolerance test indicates an improvement in the glucose-
stimulated insulin response. FRG’s beneficial effect on post-
prandial glucose concentration may be due to its direct
effects on glucose absorption into the portal circulation
[32,33], by improving insulin secretion from the pancreatic
β-cells [34], or by removing glucose from the systemic
circulation. Additionally, FRG could act indirectly by de-
creasing body weight or by lowering the plasma levels of
toxic molecules such as oxygen free radicals and free fatty
acids. Despite the lack of sufficient mechanistic studies,
our findings of an improved glycemic response in the FRG
group are consistent with those of Trinh et al. [18], who
demonstrated improved glycemic responses in hypertriglyceri-
demic mice following supplementation with Bifidobacterium-
Table 4 Effect of FRG supplementation on lipid levels
Placebo group (n = 21) FRG group (n = 21) p-value2)
Baseline Week 4 p-value1) Baseline Week 4 p-value1)
Total cholesterol (mmol/l) 4.9 ± 0.2 4.8 ± 0.2 NS 5.4 ± 0.2 4.9 ± 0.2 0.008 NS
HDL cholesterol (mmol/l) 1.2 ± 0.1 1.1 ± 0.1 0.022 1.3 ± 0.1 1.2 ± 0.1 0.014 NS
LDL cholesterol (mmol/l) 3.1 ± 0.2 2.8 ± 0.2 0.005 3.3 ± 0.2 2.9 ± 0.2 0.025 NS
Triglycerides (mmol/l) 1.6 ± 0.2 1.7 ± 0.2 NS 1.6 ± 0.2 1.9 ± 0.2 NS NS
1)Analyzed by linear mixed effect model and p-value represents the comparison to the baseline visit. 2)Analyzed by linear mixed effect model and p-value
represents the comparison to the placebo group. Data are presented as mean ± SEM.
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recent human study reported that ginseng or ginsenoside
therapy does not improve β-cell function or insulin sensi-
tivity [35], suggesting that minimal bioavailability after oral
ingestion limits red ginseng’s therapeutic efficacy in
humans [35]. Given these results, in general, fermented
red ginseng has more potent pharmacological activities
than non-fermented red ginseng, and supplementation of
FRG is beneficial for both type 2 diabetic patients and
high-risk subjects with persistent impaired fasting glucose,
at least in terms of stabilizing postprandial glycemia.
In this study, fasting plasma glucose levels, insulin levels,
and lipid profiles were not different between the two study
groups. In most human studies, improved fasting glycemia
is expected over the long-term, whereas postprandial gly-
cemia has been known to be more sensitive to small per-
turbations in glycemic control [36]. In addition, ginseng
has been reported to improve blood lipid profiles. Studies
by Kim et al. [34] and Yamamoto et al. [34] showed that
high-dose (4.5 g/day) or long-term (eight weeks) ginseng
supplementation improves dyslipidemia, decreases tri-
glycerides, and increases HDL cholesterol. In this study,
we supplemented subjects with a relatively lower dose
(2.7 g/day) for a shorter period of time (four weeks), which
might explain the lack of significant changes in fasting glu-
cose, insulin, and the lipid profile.
The limitations of this study should be considered.
First, this study was limited to a small number of sub-
jects. Therefore, caution should be used in generalizing
these results to other populations. However, these results
are generally consistent with other studies reporting de-
creasing blood glucose responses and increasing insulin
levels. Second, this study was only four weeks in dur-
ation, and thus, we only evaluated the short-term effects
of FRG supplementation on our study outcomes. Finally,
this study was a comparison study with a placebo group,
wherein the psychological effects of the placebo and the
effects of the placebo components were not considered.
In conclusion, for the first time, the results of this
study demonstrated that FRG supplementation has the
potential to improve postprandial plasma glucose levels
and to increase insulin levels. These results suggest that
FRG supplementation may be beneficial for individualswith impaired fasting glucose or type 2 diabetes. Further
studies with a larger number of subjects over a longer
duration are needed.
Conclusion
In conclusion, the results of this study demonstrated for
the first time that FRG supplementation has the potential
to improve postprandial plasma glucose levels and to in-
crease insulin levels. These results suggest that FRG supple-
mentation may be beneficial for individuals with impaired
fasting glucose or type 2 diabetes. Further studies with a
larger number of subjects over a longer duration and com-
parative studies between fermented red ginseng and non-
fermented red ginseng are needed.Additional file
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